Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies

PHASE3CompletedINTERVENTIONAL
Enrollment

336

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Psoriasis
Interventions
DRUG

U0267

All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).

DRUG

Vehicle

All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).

Trial Locations (13)

10029

Mount Sinai School of Medicine, Department of Dermatology, New York

27262

Dermatology Consulting Services, High Point

33136

Florida Academic Dermatology Centers, Miami

33175

FXM Research, Miami

40217

DermResearch, PLLC, Louisville

55432

Minnesota Clinical Study Center, Fridley

75230

Dermatology Treatment & Research Center, Dallas

77056

The Center for Skin Research, Houston

80209

Cherry Creek Research, Inc., Denver

84124

Dermatology Research Center, Inc., Salt Lake City

92123

Therapeutics Clinical Research Center, Inc., San Diego

97223

Oregon Medical Research Center, P.C., Portland

02114

Massachusetts General Hospital Clinical Unit for Research Trials in Skin, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Stiefel, a GSK Company

INDUSTRY

NCT00688519 - Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies | Biotech Hunter | Biotech Hunter